Levodopa-related wearing-off in Parkinson's disease: Identification and management

Current Medical Research and Opinion

Volumn 25, Issue 4, 2009, Pages 841-849

  Pahwa, Rajesh ^a   Lyons, Kelly E ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Levodopa; Motor complications; Parkinson's disease; Wearing off

Indexed keywords

BROMOCRIPTINE MESILATE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

DISEASE COURSE; DOCTOR PATIENT RELATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; HEALTH CARE PERSONNEL; HUMAN; LIVER TOXICITY; PARKINSON DISEASE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT REFERRAL; REVIEW; RURAL AREA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; COST OF ILLNESS; DISABLED PERSONS; DISEASE PROGRESSION; DRUG THERAPY; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; HEALTH SURVEYS; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; QUESTIONNAIRES; TIME FACTORS;

EID: 67649371216     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902779319     Document Type: Review

References (38)

1. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56:S1-S88
2. Strickland D, Bertoni JM. Parkinson's prevalence estimated by a state registry. Mov Disord 2004;19:318-323 (Pubitemid 38961087)
3. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184
4. Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-1454 (Pubitemid 43072653)
5. Agid Y, Olanow CW, Mizuno Y. Levodopa: why the controversy? Lancet 2002;360:575
6. Hoehn MM. The natural history of Parkinson's disease in the prelevodopa and post-levodopa eras. Neurol Clin 1992;10:331-339
7. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-1926 (Pubitemid 23318856)
8. Zappia M, Oliveri RL, Montesanti R, et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 1999;52:763-767 (Pubitemid 29120181)
9. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305
10. Adler CH. Relevance of motor complications in Parkinson's disease. Neurology 2002;58:51-56 (Pubitemid 34163500)
11. Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 2003;9:73-81 (Pubitemid 36952524)
12. Obeso JA, Rodriguez-Oroz MC, Chana P, et al. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000;55:S13-20; discussion S1-3
13. Lieberman A, Vijay M. Wearing-off of greatest concern for PD patient. Eur J Neurol 2004;11:S109 (Abstr P1284)
14. Koller W, Vijay M. Physician beliefs and practices in levodopa therapy for PD: results of a US National Survey. Eur J Neurol 2004;11:S9-35
15. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199 (Pubitemid 40361122)
16. Colosimo C, De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999;6:1-21 (Pubitemid 29092353)
17. Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31 (Pubitemid 24205820)
18. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23:S2-7 (Pubitemid 30949970)
19. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55:S72-7; discussion S8-81
20. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004;62:S72-81
21. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004;62:S56-63 (Pubitemid 38082853)
22. Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910 (Pubitemid 40973452)
23. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562
24. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458 (Pubitemid 36041148)
25. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov Disord 1998;13:885-894 (Pubitemid 28517664)
26. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005;20:726-733 (Pubitemid 41051784)
27. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508
28. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-413 (Pubitemid 34857934)
29. Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996;47:1180-1183 (Pubitemid 26374883)
30. Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand 2001;104:312-315 (Pubitemid 32977153)
31. Thanvi BR, Munshi SK, Vijaykumar N, et al. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad Med J 2003;79:561-565 (Pubitemid 37445249)
32. Stacy M, Hauser R, Oertel W, et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006;29:312-321 (Pubitemid 44729942)
33. Stacy MA, Murphy JM, Greeley DR, et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008;14:205-212
34. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-1507 (Pubitemid 43072661)
35. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995 (Pubitemid 44044780)
36. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13:1186-1202 (Pubitemid 44581465)
37. Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539
38. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115 (Pubitemid 46559844)